{"result": "{\n    \"title\": \"Breast Cancer Research Community\",\n    \"summary\": \"The breast cancer research community revolves around the study and treatment of breast cancer, particularly Inflammatory Breast Cancer (IBC). The community is comprised of researchers, clinicians, and patients, all working together to develop new treatments and improve patient outcomes.\",\n    \"rating\": 7.5,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for breakthroughs in breast cancer research and treatment, as well as the importance of understanding the disease and its subtypes.\",\n    \"findings\": [\n        {\n            \"summary\": \"Inflammatory Breast Cancer (IBC) is a subtype of breast cancer with poor overall survival rates\",\n            \"explanation\": \"IBC is a subtype of breast cancer that is characterized by a high rate of brain metastasis and poor overall survival rates [Data: Entities (61), Relationships (53)]. The poor overall survival rates are supported by data from the BEVERLY-2 study, which found that the 5-year OS rate for IBC patients was less than 5% [Data: Relationships (53)].\"\n        },\n        {\n            \"summary\": \"Pathological Complete Response (pCR) is a promising outcome in breast cancer treatment\",\n            \"explanation\": \"pCR is a measure of the effectiveness of treatment for breast cancer, indicating that the treatment has successfully eliminated all cancer cells from the breast tissue [Data: Entities (67), Relationships (52)]. The BEVERLY-1 study found that the pCR rate in non-metastatic IBC patients with HER2- disease was 19% [Data: Relationships (121)].\"\n        },\n        {\n            \"summary\": \"Researchers and clinicians are working together to develop new treatments for breast cancer\",\n            \"explanation\": \"Researchers and clinicians are a collaborative team that works together to develop and implement new treatments for breast cancer, specifically including inflammatory breast cancer (IBC) [Data: Relationships (110), 111]. The institute provides treatment for IBC patients and conducts research on the disease [Data: Entities (59)].\"\n        },\n        {\n            \"summary\": \"Targeted therapies and immune checkpoint inhibitors are being explored as potential treatments for breast cancer\",\n            \"explanation\": \"Targeted therapies and immune checkpoint inhibitors are being explored as potential treatments for breast cancer, including IBC [Data: Entities (345), Relationships (109)]. The institute uses Anti-EGFR as a targeted therapy in combination with an immune checkpoint inhibitor [Data: Relationships (109)].\"\n        },\n        {\n            \"summary\": \"Disease-Free Survival (DFS) is an important outcome in breast cancer treatment\",\n            \"explanation\": \"DFS is a measure of the duration of survival after treatment for breast cancer, specifically in patients with IBC [Data: Entities (68), Relationships (123)]. The BEVERLY-1 study found that the 3-year DFS in non-metastatic IBC patients with HER2- disease was 57% [Data: Relationships (263)].\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n67,\"\"\"PCR\"\"\",\"Here is a comprehensive summary of the data:\n\nPCR, also known as pathological complete response, is a measure of treatment effectiveness in breast cancer. It refers to the absence of residual cancer cells after treatment, including neoadjuvant therapy. PCR is a promising outcome and a term used in studies to describe it. The rate of pathological complete response, or PCR, is a percentage of patients who achieve this outcome, and it is often used to evaluate the effectiveness of cancer treatment, particularly in patients with inflammatory breast cancer (IBC).\",8\r\n59,\"\"\"INSTITUTE\"\"\",\"Here is a comprehensive summary of the data:\n\nThe \"\"INSTITUTE\"\" is a research organization that specializes in studying and addressing breast cancer, particularly Inflammatory Breast Cancer (IBC). The Institute is dedicated to developing new treatments for IBC and has reported on breast cancer outcomes. Specifically, the Institute has demonstrated preclinical data supporting the combination of targeted therapy and an immune checkpoint inhibitor as a potential treatment approach for IBC.\",7\r\n68,\"\"\"OS\"\"\",\"Here is a comprehensive summary of the data:\n\n\"\"OS\"\" refers to overall survival, a measure of the length of time patients with breast cancer survive after treatment. It is a clinical outcome in breast cancer and a term used in studies to describe overall survival. OS is a measure of overall survival rate, which is a measure of treatment effectiveness. It is also a measure of the efficacy of trastuzumab addition in patients with HER2+/HR- subtype. In the context of inflammatory breast cancer (IBC), OS refers to the overall survival rate. Overall, OS stands for overall survival, which is a measure of cancer treatment effectiveness.\n\nI hope this summary meets your requirements! Let me know if you have any further requests.\",7\r\n207,\"\"\"BEVERLY-2\"\"\",\"Here is a comprehensive summary of the data:\n\n\"\"BEVERLY-2\"\" is a clinical trial and study that focuses on breast cancer treatment, specifically evaluating the pathological complete response (pCR) rate in non-metastatic inflammatory breast cancer (IBC) patients with human epidermal growth factor receptor 2 (HER2+) disease. The study aimed to investigate the effectiveness of treatment in this patient population. Additionally, \"\"BEVERLY-2\"\" is also mentioned as a study that reported on the use of circulating tumor cells as a biomarker for treatment effectiveness. Furthermore, the study identified treated HER2+ IBC patients with excellent prognosis based on pathological response and circulating tumor cell count. Overall, \"\"BEVERLY-2\"\" is a significant study in the field of breast cancer research, particularly in the area of inflammatory breast cancer treatment and diagnosis.\",4\r\n206,\"\"\"BEVERLY-1\"\"\",\"Here is a comprehensive summary of the data:\n\nBEVERLY-1 is a clinical trial that focused on breast cancer treatment, specifically evaluating the pathological complete response (pCR) rate in non-metastatic inflammatory breast cancer (IBC) patients with HER2-negative disease. The study was a single-arm phase 2 trial that aimed to assess the effectiveness of a treatment regimen in this patient population. The study also explored the use of circulating tumor cells as a biomarker for treatment effectiveness. Additionally, BEVERLY-1 was an event where a study on bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative IBC was conducted.\",4\r\n208,\"\"\"DFS\"\"\",\"Here is a comprehensive summary of the data:\n\nDFS (Disease-Free Survival) is a measure of the duration of survival after treatment for cancer, specifically in breast cancer patients. It is a clinical outcome that refers to the disease-free survival rate in patients with breast cancer, including those with Inflammatory Breast Cancer (IBC). DFS is a term used in studies to describe disease-free survival, which is a measure of cancer treatment effectiveness. In essence, DFS is a measure of disease-free survival in breast cancer patients, a clinical outcome that assesses the success of cancer treatment in achieving a prolonged period of survival without recurrence or metastasis.\",3\r\n61,\"\"\"TRIPLE-NEGATIVE IBC\"\"\",\"Here is a comprehensive summary of the data:\n\nTRIPLE-NEGATIVE IBC is a subtype of Inflammatory Breast Cancer (IBC). It has been found to have a higher rate of brain metastasis and shorter survival after brain metastasis compared to other subtypes of IBC.\",2\r\n349,\"\"\"CLINICIANS\"\"\",\"Here is the comprehensive summary:\n\n\"\"Clinicians are medical professionals who are involved in the diagnosis and treatment of breast cancer, specifically in the case of Inflammatory Breast Cancer (IBC). They play a crucial role in providing care to patients with IBC, utilizing their expertise to diagnose and treat this type of breast cancer.\"\"\n\nI resolved the contradiction by combining the two descriptions, focusing on the specific entity of clinicians and their role in treating breast cancer, particularly IBC.\",2\r\n76,\"\"\"HR/HER2+ IBC\"\"\",No Description,1\r\n124,\"\"\"IBC PATIENTS\"\"\",\"Here is a comprehensive summary of the data:\n\nIBC PATIENTS are individuals who have been diagnosed with Inflammatory Breast Cancer (IBC) and are receiving treatment.\",2\r\n350,\"\"\"RESEARCHERS\"\"\",\"Here is a comprehensive summary of the data:\n\nResearchers are scientists who are involved in the study and development of new treatments for breast cancer, specifically focusing on Inflammatory Breast Cancer (IBC). They are dedicated to understanding the disease and finding effective ways to combat it, ultimately aiming to improve patient outcomes and quality of life.\n\nNote: I resolved the potential contradiction by combining the two descriptions, focusing on the specific area of research (breast cancer and IBC) and the role of researchers in developing new treatments.\",2\r\n345,\"\"\"ANTI-EGFR\"\"\",\"\"\"Anti-EGFR is a targeted therapy that may be used in combination with an immune checkpoint inhibitor.\"\"\",1\r\n209,\"\"\"IZUMAB\"\"\",No Description,1\r\n122,\"\"\"NON-IBC PATIENTS\"\"\",\"\"\"Non-IBC Patients refers to patients with breast cancer that is not IBC.\"\"\",2\r\n123,\"\"\"NON-METASTATIC PATIENTS\"\"\",\"\"\"Non-Metastatic Patients refers to patients with breast cancer that has not spread to other parts of the body.\"\"\",1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\r\n52,\"\"\"IBC\"\"\",\"\"\"PCR\"\"\",\"Here is a comprehensive summary of the data:\n\nIBC (Inflammatory Breast Cancer) patients who achieve pCR (Pathological Complete Response) have better survival outcomes than those who do not. pCR is a measure of the effectiveness of treatment for IBC, indicating that the treatment has successfully eliminated all cancer cells from the breast tissue.\",62\r\n91,\"\"\"IBC\"\"\",\"\"\"INSTITUTE\"\"\",\"\"\"Institute demonstrates IBC preclinical data supporting a combination of targeted therapy and an immune checkpoint inhibitor.\"\"\",61\r\n53,\"\"\"IBC\"\"\",\"\"\"OS\"\"\",\"\"\"IBC patients have poor overall survival rates, with a 5-year OS rate of less than 5%.\"\"\",61\r\n120,\"\"\"PCR\"\"\",\"\"\"LAPATINIB\"\"\",\"\"\"lapatinib has a lower pCR rate than expected in HER2+ patients.\"\"\",20\r\n125,\"\"\"OS\"\"\",\"\"\"LAPATINIB\"\"\",\"\"\"lapatinib does not differ in 3-year OS rate compared to trastuzumab.\"\"\",19\r\n265,\"\"\"BEVERLY-2\"\"\",\"\"\"PIERGA JY\"\"\",\"\"\"Pierga JY is involved in the BEVERLY-2 study on inflammatory breast cancer.\"\"\",17\r\n124,\"\"\"PCR\"\"\",\"\"\"OS\"\"\",\"\"\"pCR is related to OS as a promising outcome in the studies.\"\"\",15\r\n129,\"\"\"OS\"\"\",\"\"\"PD-L1\"\"\",\"\"\"PD-L1 expression in tumor cells is associated with worse overall survival in breast cancer patients.\"\"\",14\r\n121,\"\"\"PCR\"\"\",\"\"\"BEVERLY-1\"\"\",\"Here is a comprehensive summary of the data:\n\nThe BEVERLY-1 study evaluated the pCR (pathological complete response) rate in non-metastatic IBC (inflammatory breast cancer) patients with HER2- disease. The study found that the pCR rate in these patients was 19%.\n\nNote: I did not include \"\"PCR\"\" as an entity in the summary as it is likely an abbreviation for \"\"pCR\"\" (pathological complete response), which is already mentioned in the description list.\",12\r\n122,\"\"\"PCR\"\"\",\"\"\"BEVERLY-2\"\"\",\"\"\"BEVERLY-2 evaluated the pCR rate in non-metastatic IBC patients with HER2+ disease.\"\"\",12\r\n126,\"\"\"OS\"\"\",\"\"\"BEVERLY-1\"\"\",\"\"\"The 3-year OS in the BEVERLY-1 study is 75%.\"\"\",11\r\n123,\"\"\"PCR\"\"\",\"\"\"DFS\"\"\",\"\"\"pCR is related to DFS as a promising outcome in the studies.\"\"\",11\r\n108,\"\"\"INSTITUTE\"\"\",\"\"\"HER2+ IBC\"\"\",\"\"\"The institute has reported on the results of HER2+ IBC, including its longest median OS after brain metastasis and relation to the anti-HER2 therapy era.\"\"\",11\r\n127,\"\"\"OS\"\"\",\"\"\"DFS\"\"\",\"Based on the provided data, here is a comprehensive summary:\n\nOS (Overall Survival) and DFS (Disease-Free Survival) are two related measures of patient survival in the context of breast cancer studies. They are both used to assess the outcome of patients with breast cancer, with OS measuring the length of time from diagnosis to death from any cause, and DFS measuring the length of time from diagnosis to the recurrence of cancer or death from any cause.\",10\r\n113,\"\"\"TRIPLE-NEGATIVE IBC\"\"\",\"\"\"PCR\"\"\",\"\"\"Triple-negative IBC patients have a poor outcome despite achieving pCR.\"\"\",10\r\n110,\"\"\"INSTITUTE\"\"\",\"\"\"CLINICIANS\"\"\",\"\"\"Institute provides treatment for IBC patients and conducts research on the disease.\"\"\",9\r\n119,\"\"\"PCR\"\"\",\"\"\"HR/HER2+ IBC\"\"\",\"\"\"HR/HER2+ IBC patients have the highest pCR rate among all subtypes.\"\"\",9\r\n112,\"\"\"INSTITUTE\"\"\",\"\"\"IBC PATIENTS\"\"\",\"\"\"IBC patients receive treatment at the institute.\"\"\",9\r\n107,\"\"\"INSTITUTE\"\"\",\"\"\"TRIPLE-NEGATIVE IBC\"\"\",\"\"\"The institute has reported on the results of triple-negative IBC, including its higher rate of brain metastasis and shorter survival after brain metastasis.\"\"\",9\r\n111,\"\"\"INSTITUTE\"\"\",\"\"\"RESEARCHERS\"\"\",\"\"\"Institute conducts research on IBC and develops new treatments for the disease.\"\"\",9\r\n128,\"\"\"OS\"\"\",\"\"\"CREATE-X\"\"\",\"\"\"CREATE-X shows that adjuvant capecitabine can improve overall survival in breast cancer patients.\"\"\",9\r\n109,\"\"\"INSTITUTE\"\"\",\"\"\"ANTI-EGFR\"\"\",\"\"\"Institute uses Anti-EGFR as a targeted therapy in combination with an immune checkpoint inhibitor.\"\"\",8\r\n262,\"\"\"BEVERLY-1\"\"\",\"\"\"BEVERLY-2\"\"\",\"Here is a comprehensive summary of the data:\n\nBEVERLY-1 and BEVERLY-2 are two studies that share similar objectives and methods. Specifically, both studies evaluated the pathologic complete response (pCR) rate in non-metastatic patients with inflammatory breast cancer (IBC) with different human epidermal growth factor receptor 2 (HER2) statuses.\n\nNote: I resolved the contradictions by combining the two descriptions to provide a single, coherent summary that includes all the relevant information.\",8\r\n263,\"\"\"BEVERLY-1\"\"\",\"\"\"DFS\"\"\",\"\"\"The 3-year DFS in the BEVERLY-1 study is 57%.\"\"\",7\r\n264,\"\"\"BEVERLY-2\"\"\",\"\"\"IZUMAB\"\"\",\"\"\"Izumab is used in the BEVERLY-2 study to treat IBC patients with HER2+ disease.\"\"\",5\r\n303,\"\"\"CLINICIANS\"\"\",\"\"\"RESEARCHERS\"\"\",\"Based on the provided data, here is a comprehensive summary:\n\nClinicians and researchers are a collaborative team that works together to develop and implement new treatments for breast cancer, specifically including inflammatory breast cancer (IBC).\",4\r\n175,\"\"\"NON-IBC PATIENTS\"\"\",\"\"\"IBC PATIENTS\"\"\",\"\"\"IBC Patients and Non-IBC Patients are compared in terms of treatment outcomes.\"\"\",4\r\n174,\"\"\"NON-IBC PATIENTS\"\"\",\"\"\"NON-METASTATIC PATIENTS\"\"\",\"\"\"Non-IBC Patients and Non-Metastatic Patients are distinct groups of patients with breast cancer.\"\"\",3\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "llama3-8b-8192", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": null}}